[177Lu]Lu-PSMA治疗转移性去势抵抗性前列腺癌后治疗相关髓系肿瘤的病例系列
该单中心回顾性分析纳入381例接受[177Lu]Lu-PSMA治疗的mCRPC患者,发现5例(1.3%)在治疗后诊断为治疗相关髓系肿瘤(t-MN),中位年龄78岁,从第1周期到t-MN诊断中位时间33.6个月。作者认为在化疗后的mCRPC人群中t-MN发生率低,需持续随访以明确真实发生率。
要点
- 381例接受[177Lu]Lu-PSMA治疗的mCRPC患者中5例(1.3%)发生t-MN。
- 自第1周期至t-MN诊断中位时间33.6个月(范围6.0-58.8个月)。
- 所有t-MN患者骨髓遗传学分析均显示不良核型或突变。
核心结论
- 在化疗后的mCRPC人群中,[177Lu]Lu-PSMA治疗后t-MN发生率低。
- 需要持续随访以进一步明确t-MN或其他意外迟发毒性的真实发生率,尤其是在疾病病程更早期使用[177Lu]Lu-PSMA时。
研究设计与样本
- 单中心回顾性分析,回顾所有接受[177Lu]Lu-PSMA治疗的mCRPC患者。
- 对治疗期间或治疗后经活检证实发生t-MN的患者以描述性统计进行总结。
- 2015年8月26日至2022年12月31日期间,381例接受[177Lu]Lu-PSMA治疗的患者中5例(1.3%)随后诊断为t-MN。
主要发现
- 5例患者第1周期时中位年龄78岁(范围65-80岁)。
- 从第1周期到t-MN诊断的中位时间为33.6个月(范围6.0-58.8个月)。
- 既往治疗包括多西他赛(5例)、转移灶外照射放疗(5例)、阿比特龙(4例)、恩扎卢胺(3例)和卡巴他赛(3例)。
- PSMA PET/CT显示4例(80%)以骨转移为主,1例(20%)以淋巴结转移为主。
- 接受[177Lu]Lu-PSMA-617治疗3例、[177Lu]Lu-PSMA-I&T治疗2例,中位7个周期(范围4-12个周期),中位总累积活度49.2 GBq(范围31.3-79.0 GBq)。
关键数值与推荐
- 381例接受[177Lu]Lu-PSMA治疗的mCRPC患者中5例(1.3%)发生t-MN。
- 从第1周期到t-MN诊断中位时间33.6个月(范围6.0-58.8个月)。
- 中位总累积活度49.2 GBq(范围31.3-79.0 GBq),中位7个周期(范围4-12个周期)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
[177Lu]Lu-prostate-specific membrane antigen (PSMA) therapy has a favorable toxicity profile in patients with metastatic castration-resistant prostate cancer (mCRPC). Therapy-related myeloid neoplasm (t-MN) has been described after [177Lu]Lu-DOTATATE but has not, to our knowledge, yet been reported after [177Lu]Lu-PSMA. This case series describes 5 patients with mCRPC who developed t-MN after [177Lu]Lu-PSMA at our institution. Methods: In this single-center retrospective analysis, we reviewed all patients with mCRPC treated with [177Lu]Lu-PSMA. Patients who developed biopsy-proven t-MN during or after [177Lu]Lu-PSMA treatments are summarized with descriptive statistics. Results: From August 26, 2015, to December 31, 2022, 5 of 381 (1.3%) patients treated with [177Lu]Lu-PSMA were subsequently diagnosed with t-MN. Their median age at cycle 1 (C1) was 78 y (range, 65-80 y). The median time from C1 to t-MN diagnosis was 33.6 mo (range, 6.0-58.8 mo). Previous treatments included docetaxel (n = 5), external-beam radiotherapy to metastases (n = 5), abiraterone (n = 4), enzalutamide (n = 3), and cabazitaxel (n = 3). On PSMA PET/CT, 4 (80%) patients had predominantly bone metastases and 1 (20%) had predominantly nodal metastases. They were treated with [177Lu]Lu-PSMA-617 (n = 3) or [177Lu]Lu-PSMA-I&T (n = 2). A median of 7 cycles (range, 4-12 cycles) of [177Lu]Lu-PSMA was administered, with a median total cumulative activity of 49.2 GBq (range, 31.3-79.0 GBq). Prostate-specific antigen reduction of at least 50% or at least 80% from baseline was seen in 5 (100%) and 4 (80%), respectively. All had prostate-specific antigen progression preceding t-MN diagnosis. t-MN diagnosis included myelodysplastic syndrome with single-lineage dysplasia (n = 2), myelodysplastic syndrome with excess blasts 1 (n = 1), acute promyelocytic leukemia (n = 1), and acute myeloid leukemia (n = 1). At t-MN diagnosis, all patients presented with at least grade 2 cytopenia, involving one or more blood cell lines. Marrow genetic analysis revealed unfavorable karyotypes or mutations in all patients. Most patients received supportive care after t-MN diagnosis. Survival was 8.1, 31.3, 43.0, 56.0, and 60.4 mo from C1 and 1.8, 2.1, 6.8, 10.3, and 12.4 mo from t-MN diagnosis. Conclusion: In the mCRPC population after chemotherapy, we describe a low incidence of t-MN after [177Lu]Lu-PSMA therapy. Ongoing follow-up is necessary to further define the true incidence of t-MN or other unexpected delayed toxicities, particularly with earlier use of [177Lu]Lu-PSMA in the disease course.
引用
- Eifer M, Sutherland DEK, Goncalves I, et al. Therapy-Related Myeloid Neoplasms After [177Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series. J Nucl Med. 2025. PMID: 39978813. doi:10.2967/jnumed.124.268640
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。